0000899243-20-020587.txt : 20200729 0000899243-20-020587.hdr.sgml : 20200729 20200729060637 ACCESSION NUMBER: 0000899243-20-020587 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200728 FILED AS OF DATE: 20200729 DATE AS OF CHANGE: 20200729 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanofi CENTRAL INDEX KEY: 0001121404 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 201055622 BUSINESS ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 BUSINESS PHONE: 33153774400 MAIL ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 FORMER NAME: FORMER CONFORMED NAME: SANOFI-AVENTIS DATE OF NAME CHANGE: 20040826 FORMER NAME: FORMER CONFORMED NAME: SANOFI SYNTHELABO SA DATE OF NAME CHANGE: 20010104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inozyme Pharma, Inc. CENTRAL INDEX KEY: 0001693011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 475129768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-330-4340 MAIL ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Inozyme Pharma, LLC DATE OF NAME CHANGE: 20161222 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-28 1 0001693011 Inozyme Pharma, Inc. INZY 0001121404 Sanofi 54 RUE DE LA BOETIE PARIS I0 75008 FRANCE 0 0 1 0 Common Stock (par value $0.0001) 2020-07-28 4 C 0 438875 0.00 A 438875 I Through its wholly-owned subsidiary, Aventis Inc. Common Stock (par value $0.0001) 2020-07-28 4 P 0 81250 16.00 A 520125 I Through its wholly-owned subsidiary, Aventis Inc. Series A Convertible Preferred Stock (par value, $0.0001) 0.00 2020-07-28 4 C 0 3279720 0.00 D Common Stock 438875 0 I Through its wholly-owned subsidiary, Aventis Inc. On July 28, 2020, Series A Convertible Preferred Stock (par value, $0.0001) converted into the Issuer's Common Stock on a 7.473-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of INZY and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of INZY. The reporting person acquired additional shares in the Issuer's initial public offering. /s/ Alexandra Roger, Head of Securities Law and Capital Markets 2020-07-29